Vor Biopharma annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Vor Biopharma Depreciation & Amortization Growth & History (VOR)
Vor Biopharma's depreciation and amortization was $2.9M for fiscal 2025.
View full Vor Biopharma company overviewVor Biopharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.9M | −$641,000 | −18.17% |
| 2024 | 2024-12-31 | $3.5M | $36,000 | +1.03% |
| 2023 | 2023-12-31 | $3.5M | $967,000 | +38.30% |
| 2022 | 2022-12-31 | $2.5M | $1.1M | +76.08% |
| 2021 | 2021-12-31 | $1.4M | $829,000 | +137.02% |
| 2020 | 2020-12-31 | $605,000 | — | — |
Vor Biopharma quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $36,000 | −$2.1M | −98.29% |
| Q1 2026 | 2026-03-31 | $28,000 | −$797,000 | −96.61% |
| Q4 2025 | 2025-12-31 | $23,000 | — | — |
| Q3 2025 | 2025-09-30 | $2,000 | −$898,000 | −99.78% |
| Q2 2025 | 2025-06-30 | $2.1M | $1.2M | +133.33% |
| Q1 2025 | 2025-03-31 | $825,000 | −$118,000 | −12.51% |
| Q3 2024 | 2024-09-30 | $900,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $900,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $943,000 | $106,000 | +12.66% |
| Q3 2023 | 2023-09-30 | $900,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $900,000 | $300,000 | +50.00% |
| Q1 2023 | 2023-03-31 | $837,000 | $411,000 | +96.48% |
| Q3 2022 | 2022-09-30 | $900,000 | $600,000 | +200.00% |
| Q2 2022 | 2022-06-30 | $600,000 | $200,000 | +50.00% |
| Q1 2022 | 2022-03-31 | $426,000 | $115,000 | +36.98% |
| Q3 2021 | 2021-09-30 | $300,000 | $100,000 | +50.00% |
| Q2 2021 | 2021-06-30 | $400,000 | $300,000 | +300.00% |
| Q1 2021 | 2021-03-31 | $311,000 | $245,000 | +371.21% |
| Q3 2020 | 2020-09-30 | $200,000 | — | — |
| Q2 2020 | 2020-06-30 | $100,000 | — | — |
| Q1 2020 | 2020-03-31 | $66,000 | — | — |
Vor Biopharma depreciation and amortization trends
Over the last five fiscal years, Vor Biopharma's depreciation and amortization increased from $605,000 to $2.9M, a change of $2.3M. The latest reported quarter, Q2 2026, shows $36,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vor Biopharma source filings ↗